Celtaxsys is focused on developing new drugs to treat inflammatory diseases. Celtaxsys’ clinical program includes CTX-4430, a first-in-class oral LTA4 Hydrolase inhibitor for treatment of pulmonary inflammation associated with Cystic Fibrosis.
An Inflammatory Disease is a condition caused by improper regulation of the innate immune system. Celtaxsys is discovering new oral medicines to treat several underserved pulmonary and systemic inflammatory diseases.
Innate Immunity is an ancient protective system that is active from birth and serves as our first line of defense. This system is now known to be important in both promoting and resolving inflammation. Celtaxsys is developing new ways to modulate innate immunity to reduce inflammation and promote resolution.
The Neutrophil is one of the most mobile and potentially destructive cell types in the body. Celtaxsys is pioneering new ways of modulating neutrophil movement to inflamed tissues through new drugs that selectively control immune attraction and repulsion.
Celtaxsys is a clinical-stage specialty pharmaceutical company focused on therapeutics that control pulmonary inflammatory disease through innate immunity.